Recurrent or metastatic cervical cancer (RMCC) remains one of the most challenging malignancies to treat, with median overall survival rarely exceeding 13 to 17 months despite recent advances. Since ...
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) ...
Cervical cancer incidence has declined close to 30% among women aged 20 to 31 years since the start of the millennium, but certain states have achieved significantly greater reductions.Washington, D.C ...
"The release of ESMO-MCBS v2.0 marks a major step forward in ESMO's mission to promote value-based cancer care, and clearly reflects ESMO's ongoing commitment to ensuring that the scale remains a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results